Amarin (NASDAQ:AMRN) Announces Earnings Results, Beats Expectations By $0.02 EPS

Amarin (NASDAQ:AMRN) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02, Yahoo Finance reports. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. The firm had revenue of $56.52 million during the quarter, compared to analyst estimates of $51.34 million. During the same period last year, the firm posted ($0.04) EPS.

Amarin Trading Up 6.6 %

Shares of AMRN stock traded up $0.06 on Thursday, hitting $0.90. 790,349 shares of the stock were exchanged, compared to its average volume of 1,932,692. The firm has a market capitalization of $367.55 million, a PE ratio of -6.05 and a beta of 1.95. Amarin has a one year low of $0.65 and a one year high of $1.49. The firm’s 50 day moving average is $0.95 and its two-hundred day moving average is $0.94.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, Amarin currently has an average rating of “Hold” and an average target price of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.